Related Articles for PubMed (Select 16138923)

Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.

Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, Sterry W, Baumann G, Trefzer U.

Cardiovasc Ultrasound. 2005 Sep 2;3:26.

PMID: 16138923 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F.

J Am Coll Cardiol. 2004 Oct 6;44(7):1488-96.

PMID: 15464333 [PubMed - indexed for MEDLINE]

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

PMID: 14568893 [PubMed - indexed for MEDLINE]

Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.

Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, Hubloue I, Remmelink M, Brimioulle S, Salmon I, Ketelslegers JM, Naeije R.

Circulation. 2004 Oct 12;110(15):2220-5. Epub 2004 Oct 4.

PMID: 15466636 [PubMed - indexed for MEDLINE]

Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.

Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, Meldrum DR.

Ann Thorac Surg. 2006 Jan;81(1):272-8.

PMID: 16368379 [PubMed - indexed for MEDLINE]

Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.

Ströberg P, Hedelin H, Ljunggren C.

Eur Urol. 2006 May;49(5):900-7; discussion 907. Epub 2006 Mar 9.

PMID: 16564126 [PubMed - indexed for MEDLINE]

[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]

Rosenkranz S, Caglayan E, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E.

Dtsch Med Wochenschr. 2004 Aug 13;129(33):1736-40. German.

PMID: 15295684 [PubMed - indexed for MEDLINE]

Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.

Briganti A, Salonia A, Gallina A, Saccà A, Montorsi P, Rigatti P, Montorsi F.

Nat Clin Pract Urol. 2005 May;2(5):239-47. Review.

PMID: 16474835 [PubMed - indexed for MEDLINE]

[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]

Ghofrani HA, Grimminger F.

Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S311-4. Review. German.

PMID: 17139594 [PubMed - indexed for MEDLINE]

10:

Sildenafil citrate therapy for pulmonary arterial hypertension.

Hoeper MM, Welte T.

N Engl J Med. 2006 Mar 9;354(10):1091-3; author reply 1091-3. No abstract available.

PMID: 16525151 [PubMed - indexed for MEDLINE]

11:

Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia.

Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S.

Pediatr Crit Care Med. 2004 Mar;5(2):184-7.

PMID: 14987351 [PubMed - indexed for MEDLINE]

12:

Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.

Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet JL, Delic J, Merle-Beral H.

Blood. 2003 Jan 1;101(1):265-9. Epub 2002 Jun 28.

PMID: 12393651 [PubMed - indexed for MEDLINE]

13:

Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.

Urdaneta F, Willert JL, Beaver T, Naik B, Kirby DS, Lobato EB.

Ann Thorac Surg. 2004 Oct;78(4):1433-7.

PMID: 15464509 [PubMed - indexed for MEDLINE]

14:

Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.

Watanabe H.

Intern Med. 2004 Oct;43(10):891-3. No abstract available.

PMID: 15575233 [PubMed - indexed for MEDLINE]

15:

Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.

Steiner MK, Preston IR, Klinger JR, Hill NS.

Curr Opin Pharmacol. 2005 Jun;5(3):245-50. Review.

PMID: 15907910 [PubMed - indexed for MEDLINE]

16:

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.

PMID: 17785618 [PubMed - indexed for MEDLINE]

17:

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.

Kloner RA.

Am J Cardiol. 2005 Dec 26;96(12B):42M-46M. Epub 2005 Dec 5. Review.

PMID: 16387566 [PubMed - indexed for MEDLINE]

18:

Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome.

Miwa K, Matsubara T, Uno Y, Yasuda T, Sakata K, Tsuda T, Kanaya H.

Int Heart J. 2007 May;48(3):417-22.

PMID: 17592207 [PubMed - indexed for MEDLINE]

19:

Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L.

J Mol Cell Cardiol. 2004 Feb;36(2):165-73. Review.

PMID: 14871543 [PubMed - indexed for MEDLINE]

20:

Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy.

Derchi G, Forni GL.

Ann N Y Acad Sci. 2005;1054:471-5. Review.

PMID: 16339700 [PubMed - indexed for MEDLINE]

Recent Activity